RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究已经结束，不会有进一步的收益。 (来自国家癌症研究所的PDQ？数据库的临床试验摘要) 化疗中使用的药物，如放线菌素、环磷酰胺、长春新碱和拓扑替康，使用不同的方法阻止肿瘤细胞分裂，从而停止生长或死亡。目前还不知道哪种联合化疗方案在治疗横纹肌肉瘤方面更有效。这项随机的III期试验正在比较两种不同的联合化疗方案，看看每种方案在治疗以前没有治疗过的横纹肌肉瘤或肉瘤患者中的效果如何。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to further accrual. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma.